Lisa Boyd
Psychiatry · Conroe, TXNPI 1306025218
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 182 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 14.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,689 and has fallen 72.0% since, to $752 in 2025. Among psychiatry clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 182 payments — averaging $40.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$1K
- AbbVie$983
- Ironshore Pharmaceuticals Inc.$682
- Takeda Pharmaceuticals U.S.A., Inc.$591
- Otsuka America Pharmaceutical, Inc.$550
- Johnson & Johnson$515
- plus $3K from 21 others
What the payments were for
- Food & beverage$7,298100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 25 | $1,031 |
| AbbVie(2 entities) | 26 | $983 |
| Ironshore Pharmaceuticals Inc. | 9 | $682 |
| Takeda Pharmaceuticals U.S.A., Inc. | 28 | $591 |
| Otsuka America Pharmaceutical, Inc. | 9 | $550 |
| Johnson & Johnson | 8 | $515 |
| Vanda Pharmaceuticals Inc. | 15 | $511 |
| Corium, LLC | 6 | $312 |
| Tris Pharma Inc | 3 | $266 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $244 |
| Jazz Pharmaceuticals Inc. | 4 | $235 |
| Alkermes, Inc. | 2 | $226 |
| Axsome Therapeutics, Inc. | 4 | $167 |
| Supernus Pharmaceuticals, Inc. | 3 | $165 |
| Neos Therapeutics, LP | 9 | $149 |
| Neurocrine Biosciences, Inc. | 1 | $120 |
| Eisai Inc. | 6 | $118 |
| Bausch Health US, LLC | 6 | $107 |
| Sunovion Pharmaceuticals Inc. | 3 | $68 |
| Arbor Pharmaceuticals, Inc. | 3 | $47 |
| Lundbeck LLC | 2 | $45 |
| Adlon Therapeutics L.p. | 2 | $43 |
| Shire North American Group Inc | 2 | $41 |
| OWP Pharmaceuticals, Inc. | 1 | $24 |
| Acadia Pharmaceuticals Inc | 1 | $23 |
| Avanir Pharmaceuticals, Inc. | 1 | $21 |
| Noven Therapeutics, LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$903
- VRAYLAR$746
- AUSTEDO$465
- Jornay PM 20mg capsules (Bottle of 100)$358
- Fanapt$250
- Azstarys$249
- CAPLYTA$244
- Dyanavel XR$241
- UZEDY$238
- REXULTI$211
- QELBREE$125
- Quillichew ER$125
- Quillivant$125
- Auvelity$121
- INGREZZA$120
- SPRAVATO$113
- JORNAY PM$110
- INVEGA SUSTENNA$110
- INVEGA TRINZA$110
- XYREM$107
How this compares
$7,298 in reported general payments places this provider in the 90th percentile of 2,238 psychiatry providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 12 | $17,372 |
| TrintellixVortioxetine Hydrobromide | 13 | $6,260 |
| Paliperidone ErPaliperidone | 12 | $2,922 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 11 | $579 |
| Bupropion Hcl SrBupropion Hcl | 20 | $551 |
| Lamotrigine | 34 | $549 |
| Lorazepam | 14 | $424 |
| Clonazepam | 78 | $391 |
| Escitalopram Oxalate | 27 | $215 |
| Citalopram HbrCitalopram Hydrobromide | 14 | $213 |
| Duloxetine Hcl | 12 | $135 |
| Trazodone Hcl | 39 | $122 |
| Quetiapine Fumarate | 26 | $120 |
| Zaleplon | 12 | $79 |
| Temazepam | 12 | $66 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $550 | $17,37212 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $591 | $6,26013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,238 psychiatry providers in Texas.
Other psychiatry in Conroe
- Rakesh JainLake Jackson$7.2M
- Arvinder Pal WaliaAustin$2.5M
- Suresh SureddiPlano$2.2M
- Martin GuerreroEl Paso$2M
- Marty BennettAddison$1.8M
- Matthew BramsHouston$1.5M
- Vikram MehraKaty$1.2M
- Joel HolinerDallas$948K
- Frank ChenHouston$941K
- Alice MaoHouston$850K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.